Jade Biosciences, Inc. (JBIO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$13.56

From 52W high−48.49%

Volume828493.00

Market cap$879.55M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$13.56

From 52W high

−48.49%

Volume

828493.00

Market cap

$879.55M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.7x

P/E (TTM)

—

RSI (14)

35.3

MomentumView details →

1D Return

+2.67%

YTD Return

−10.76%

SummaryUpdated Jun 1, 2026

Jade Biosciences, Inc. (NASDAQ:JBIO) is a clinical-stage biotechnology company founded to develop innovative therapies for autoimmune diseases. The company went public in April 2025 and is headquartered in the United States. Jade Biosciences focuses specifically on addressing critical unmet medical needs in autoimmune conditions, with its lead program targeting a rare kidney disease called IgA nephropathy.

Ask drillr about Jade Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−34.83%

ROA (TTM)

−32.46%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+82.69%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+95.24%

EBITDA YoY

—

MomentumView details →

1D Return

+2.67%

YTD Return

−10.76%

1Y Return

+37.70%

RSI (14)

35.3

vs 50D SMA

−23.45%

vs 200D SMA

−24.33%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

14.93x

Quick Ratio

14.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.76

EPS Surprise

−19.42%

Beats (12Q)

3/12

Next Q EPS Est

−$0.75

Avg Surprise (4Q)

15.58%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−153.24M

Op. CF (TTM)

−123.51M

Next earningsNov 12, 2026 →

Latest newsMore news →

Jade Biosciences announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, at EADV 2026.20d ago

Jade Biosciences reported its financial results for the second quarter ending June 30, 2026, with cash, cash equivalents, and investments of $461 million as of that date, expected to provide runway into the fourth quarter of 2028.71d ago

Similar companies

Theravance Biopharma, Inc.TBPH ArriVent BioPharma, Inc. Common StockAVBP Rigel Pharmaceuticals, Inc.RIGL Odyssey Therapeutics, Inc.ODTX Alto Neuroscience, Inc.ANRO SL Science Holding Limited Ordinary SharesSLBT Find similar companies →

Latest newsMore news →

Jade Biosciences announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, at EADV 2026.20d ago Jade Biosciences reported its financial results for the second quarter ending June 30, 2026, with cash, cash equivalents, and investments of $461 million as of that date, expected to provide runway into the fourth quarter of 2028.71d ago